44 studies found for:    ARSENIC ACID
Show Display Options
Rank Status Study
21 Completed Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Promyelocytic Leukemia (M3);   Childhood Acute Promyelocytic Leukemia (M3);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: tretinoin;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: arsenic trioxide
22 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: arsenic trioxide;   Drug: mitoxantrone hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Drug: idarubicin;   Drug: tretinoin;   Drug: cytarabine;   Drug: mercaptopurine tablet;   Drug: methotrexate
23 Completed Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic
Condition: Arsenical Keratosis
Intervention: Dietary Supplement: Spirulina
24 Terminated Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
Condition: Metastatic Melanoma
Interventions: Drug: Disulfiram;   Drug: Arsenic trioxide
25 Not yet recruiting Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
26 Terminated Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage IV Esophageal Cancer
Intervention: Drug: arsenic trioxide
27 Completed Arsenic Trioxide in Treating Patients With Urothelial Cancer
Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer
Intervention: Drug: arsenic trioxide
28 Active, not recruiting Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma of the Skin;   Recurrent Skin Cancer
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
29 Terminated Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: arsenic trioxide;   Other: laboratory biomarker analysis
30 Completed Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pamidronate disodium;   Drug: arsenic trioxide;   Other: laboratory biomarker analysis;   Other: pharmacological study
31 Completed Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: arsenic trioxide;   Radiation: radiation therapy
32 Not yet recruiting Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Condition: Carcinoma, Hepatocellular
Interventions: Drug: TACE containing As2O3;   Drug: TACE containing placebo
33 Completed Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis
Condition: Arsenical Keratosis
Interventions: Other: Leaf extract of A. indica;   Drug: Salicylic Acid (6%);   Other: Petroleum jelly
34 Recruiting Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tretinoin and Arsenic Trioxide
35 Completed Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
36 Active, not recruiting S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
37 Completed Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
38 Recruiting A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Condition: Childhood Acute Promyelocytic Leukemia
Interventions: Drug: ATO;   Drug: RIF;   Drug: ATRA;   Drug: mitoxantrone;   Drug: Ara-C;   Drug: MTX;   Drug: 6MP;   Other: intrathecal injection
39 Completed Selenium in the Treatment of Arsenic Toxicity and Cancers
Conditions: Arsenical Melanosis;   Arsenical Keratosis;   Arsenical Cancers;   Arsenicosis;   Arsenic Exposure;   Arsenic Toxicity;   Arsenic Poisoning
Interventions: Drug: sodium selenite;   Drug: placebo
40 Recruiting The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization
Conditions: Ischemic Heart Disease;   Myocardial Ischemia;   Coronary Disease;   Acute Coronary Syndrome
Intervention: Device: AVI® Arsenic trioxide drug eluting stent

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-44) Show next page of results
Indicates status has not been verified in more than two years